-The Times of India The Supreme Court on Monday rejected pharma giant Novartis AG's plea to preserve its patent over a life-saving cancer drug, Glivec, drawing a huge sigh of Relief from thousands of patients in India and in dozens of developing countries as the fear of an almost 15-fold escalation of drug costs receded. It is the biggest setback for multinational pharma companies, which have been denied patent protection...

-Live Mint SC rejects Novartis's patent plea for Glivec, says it does not meet any standard of novelty or inventiveness In a landmark judgement, India's apex court rejected Swiss drug maker Novartis AG's legal challenge aimed at securing a patent for blockbuster anti-cancer drug imatinib mesylate, branded Glivec in the country. The verdict, which is seen as a setback to multinational pharmaceutical companies operating in India, may influence a rash of pending disputes...

-The Hindu   Supreme Court rejects Novartis' plea for patent; green signal for cheaper generic drugs In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a well known cancer-fighting drug is not a patentable new invention. The judgment allows suppliers to continue making generic copies of Swiss firm Novartis' Glivec or Gleevec, which has been shown to...

-PTI The Supreme Court on Tuesday asked Sterlite Industries, a subsidiary of U.K.-based Vedanta Group, to pay Rs. 100 crore as compensation for polluting environment through its copper smelting plant in Tamil Nadu but refused to direct its closure. A bench headed by Justice A.K. Patnaik said that the environment has been polluted for a long time due to the discharge from the plant of the multinational company and it has...

-The Times of India In a major setback to special economic zone (SEZ) developers, finance minister P Chidambaram has turned down the commerce department's plea to cut the minimum alternate tax (MAT), which was imposed two years ago. A lower or no tax burden was cited as one of the main drivers for boosting investment in what were until recently duty-free enclaves. The commerce department had made a case for reversing Chidambaram's...